Resonant Molecular Signaling (RMS) is a novel platform that addresses a broad spectrum of disorders via a new therapeutic approach of cellular signaling.
Based on decades of laboratory research, animal-model studies, and formal clinical trials conducted by Beech Tree investigators, the underlying theory of RMS is that a healthy state is marked by normal signaling within and between cells while disease is caused by disruption of this norm. In addition, this theory supports a view in which:
Consistent with a novel platform, the mechanisms underlying these formulations are different than current pharmacological approaches to product discovery. For instance, identifying the etiological agent for initiating disease is not important. The pathophysiologic cascade of events induced by the causative agent, or agents, is the focus. The goal of RMS therapies is to interrupt pathophysiology by selective molecular intervention—thereby restoring normal regulatory function.
As evidenced by the results of formal trials, hundreds of patients have been treated with no significant adverse side effects. Other clinical observations include:
Validation of this approach is also found in the publication of peer-reviewed papers addressing the mechanism of action and clinical efficacy of Beech Tree's therapeutic agents.